Ep 7: Prepare for ASH 2025 with LARVOL CLIN & CONF
29-November-2025
Bruno Larvol, joined by Kalpana Devi and Sweta Agrawal, discuss how LARVOL CLIN and CONF support planning for ASH 2025.
Ep 6: Celebrating Oncology Champions on the Times Square
20-November-2025
Bruno joins Shaheer LIVE from Times Square as the LARVOL billboard goes up—celebrating patient advocates, top women oncologists from @ESMO 2025, and this year’s top-performing tigers.
Ep 5 | Live from ESMO AI 2025
17-November-2025
Bruno and Judith join from the floor at #ESMOAI25 to share quick takeaways, early signals, and what’s standing out in real time. A short, direct update from inside the conference as AI and oncology conversations unfold.
Ep 4: Pre-ESMO AI 2025 Insights
11-November-2025
In this episode of LARVOL Oncology Podcast, Bruno Larvol, along with Daniel J. and David Wilkerson, discusses the Pre-ESMO AI 2025 Insights and AI SoC mapping.
Ep 3: ESMO 2025 KOL rapid readout
25-October-2025
In this episode of LARVOL Oncology Podcast, Bruno Larvol and Kalpana Devi Narisetty discuss KOL rapid readout and insights from ESMO 2025.
Ep 2: ESMO 2025 Preview
16-October-2025
In this episode of LARVOL Oncology Podcast, Bruno and Judith join Kalpana from #ESMO25 to share early impressions from the conference, discuss data trends, and reflect on how it continues to shape oncology research and decision-making.
Ep 1: Pre-ESMO 2025 Insights
10-October-2025
In this episode of LARVOL Oncology Podcast, Shaheer Shaikh and Kalpana Devi Narisetty discuss pre-ESMO 2025 insights.
Ep 7: Frequentist vs Bayesian: A Friendly Deep Dive
28-November-2025
Bruno and Darko take a light, conversational look at the long-running “frequentist vs Bayesian” divide. From Bayes’ unpublished notes to Laplace turning the idea into something bigger. A fun episode touching on how people have argued about probability for centuries and why both approaches still show up in today’s thinking.
Ep 6: From Fibonacci to the First Clinical Trial
22-November-2025
Bruno and Darko discuss the Fibonacci sequence — from rabbits to the surprising patterns it shaped — before jumping to James Lind’s scurvy experiment, one of history’s first clinical trials. A brief episode tying together math, story, and the roots of evidence-based testing.
Ep 5: Real-World Noise, Real AI Insights: Live from Times Square
17-November-2025
Darko is joined by Bruno live from Times Square to discuss AI concepts with the real-world chaos of a crowd. They talk about how unpredictable human movement mirrors the way AI models learn from massive datasets. A fast, grounded conversation linking everyday patterns in Times Square to core ideas in machine learning.
Ep 4: From Roots to Results: Tree-Based Models in Cancer Data
09-November-2025
Bruno and Darko unpack how tree-based models branch out in biostatistics and where they root themselves in real oncology data. A quick and clever look at how AI learns to see the forest and the trees at once.
Ep 3: Randomization and Data Reliability in Oncology Research
31-October-2025
Bruno and Darko discuss randomization and confounders, two core concepts in clinical research. They explore how study design, data quality, and bias control affect the reliability of trial outcomes, and how AI can help identify or adjust for confounding variables. A direct, practical talk on what truly shapes trustworthy data in oncology research.
Ep 2: AGI and Oncology
24-October-2025
Bruno and Darko talk about AGI, defining what it is, what current AI systems can actually do, and what remains speculation. They keep the focus on practical implications for oncology and data analysis, separating real capabilities from hype. A straightforward check on where AI stands today and what to expect next.
Ep 1: How AI and Biostatistics Are Shaping Oncology Research
17-October-2025
Bruno joins from #ESMO25 in Berlin for a discussion with Darko on how AI and biostatistics are shaping oncology research. They talk about data structure, model reliability, and practical ways AI is improving the analysis of clinical trials. A focused conversation on how better data leads to better cancer insights.